Dabur India Q2 FY27 Earnings Call: Guides Double-Digit Growth For FY27, Rs. 6,000 Cr War Chest For M&A

Dabur India Ltd held its Q2 FY27 earnings call on November 04, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Second Consecutive Quarter of Double-Digit Revenue Growth

• Consolidated revenue +11.6% YoY — second consecutive quarter of double-digit revenue growth and fourth quarter of double-digit PAT growth in Q2 FY 2026-2027.
• India standalone +8.9% — operating margin dilution limited to 10 bps despite inflation; India FMCG grew 10.7% (volume 5.5%, price 5.2%); international business grew 20%.
• Healthcare +6.9% — CEO Harjeet Bhalla called it a recovery but "not where we need it to be"; CFO Ankush Jain noted the rest of the healthcare portfolio grew in teens despite health supplements being challenged.
• F&B grew strong double digits — beverages bounced back on premium products (active coconut, Real Active juice) plus incremental Real investments; HPC delivered double-digit growth while mitigating bulk of HPC-led inflation.
• Margin pressure from international — operating profit was impacted by higher inflation in supply chain, freight and logistics at the international business.
• Macro headwinds — management cited the Middle East conflict driving crude prices and elevated inflation, making FMCG consumption challenging; approach is "control the controllables" via mix, cost optimization and calibrated price increases.

18 Months Into the 3-Year Vision: Mixed Scorecard, New Ignite Priorities

• Scorecard mixed at 18 months — core acceleration AMBER (committed media support fell short due to the environment); premiumization near GREEN; health & wellness AMBER; portfolio simplification GREEN; Project Saksham GREEN; strategic M&A RED; operating efficiencies near GREEN.
• Premiumization delivering — premium portfolio rose from 17% to 20% of revenue over the first 18 months of the vision, growing at 4x the overall rate and margin accretive; management targets 23% premium share over the next 18 months.
• Project Samriddhi savings — generated over Rs.115 crore during the vision period; management targets 1.5x of that level going forward (period unspecified) — CEO's rough math is ~Rs.200 crore, though his team indicates slightly lower.
• Ignite agenda — running ~3 months with four priorities (accelerate growth, execution excellence, future-ready portfolio, funding investment); includes incremental 150-200 bps of ad pro/media investment behind consumer-facing brand spend (period unspecified), tilted to OTCs, digestives, parts of skincare, home care and foods.
• Digital shift — digital media now 43% of total media spends with influencer usage up over 3x; AI used in media planning and in-house content generation (Real Activ cranberry ad).
• Strategy cadence accelerated — the next 3-year vision was due March 2028, but a strategic midterm exercise is being initiated now; management will return within the next 6-8 months with a 2031 plan covering portfolio evolution and execution.

Project Saksham Reshapes General Trade; Chemist Channel Next

• Distributor count cut 43% — distributor attrition down 80%, throughput up 2x, ROI up 30% under Project Saksham; GT has grown mid-single digits for two consecutive quarters, with Q2 FY 2026-2027 delivering the highest GT growth in ~19 quarters. Saksham is not yet complete.
• No white spaces created — management clarified the 43% consolidation merged historically separate networks (foods, healthcare, HPC) into a common distribution system without vacating geographies; CFO Ankush Jain added almost 50% of distributors were consolidated seamlessly over ~1 year with an external partner.
• Chemist channel program — CEO confirmed it is a key aspect of Project Saksham, using MSL and digitization to place the right portfolio in the right store; critical from an OTC and digestive portfolio lens. The GTM 2.0 presentation made no mention of chemist channel initiatives, per Vishal (YES Securities).
• Retail Next and rural reach — channel program being built across 40,000 stores targeting growth of 1.5x the rest of GT (period unspecified); rural direct reach to be expanded to over 100,000 villages with geotagging (period unspecified).
• Quick commerce viewed as complementary — enabling premium portfolio placement, wider lines and innovation rather than threatening GT distribution; alternate channels growing strong double digits.

Health & Wellness Named the "Right to Win" Area; Honey and Chyawanprash Revival

• Health & wellness is the top priority — CEO Harjeet Bhalla identified it as the one area where Dabur has the "right to win"; OTC and digestives are growing "incredibly strongly" while the health supplements business "has remained challenged" and needs a solve.
• Chyawanprash stagnation — analyst Mihir Shah of Nomura noted the brand has been flat for 3-4 years post-COVID; the CEO said a new TVC alone will not solve it — the plan rests on relevance-focused communication, strong distribution, strong winter loading executed for Q3 FY 2026-2027, and new formats starting with gummies, with more format work over FY 2027-2028.
• Honey traceability push — management is building traceability that will let consumers trace honey back to the beekeeper and said it will start talking about this soon (period unspecified); purity messaging amplified via influencers; honey purity campaign filmed at the Baddi (Himachal Pradesh) factory.
• Honey premiumization — organic and region-specific origins (e.g., Sundarbans) retail at ~2.5x normal honey pricing; a monofloral honey launches in November 2026; sampling initiatives enhanced at the bottom end given low penetration.
• Beverages premiumization — Real Active 100% juices and 100% no-added-sugar juices growing at strong double-digit rates with market share gains in FY 2026-2027; coconut water has done "extremely well". Nectars increasingly perceived as too sweetened, per Nihal (HSBC).
• HPC opportunities — skin care seen as an opportunity in Oxy and Gulabari; in home care, Odonil plus newly entered categories such as car and automatic diffusers offer further growth potential.

M&A Rated RED; Rs.6,000 Cr War Chest, But Discipline Prevails

• Strategic M&A rated RED — at the 18-month mark of the vision; management will pursue deals only if strategically fitting, scalable, adjacent to existing categories (no new categories) and at the right valuation.
• CEO declined an 18-month M&A timeline — analyst noted Dabur self-rated "red" versus peers Marico, Tata Consumer and ITC, who have executed multiple scaled acquisitions; CEO cited current market valuations and the need for clear benefit to Dabur from any deal.
• War chest of almost Rs.6,000 crore in India — as of Q2 FY 2026-2027, per CFO Ankush Jain; funds are available provided there is a right, synergistic acquisition at the right valuation, and management will calibrate M&A rather than acquire "just for the sake of acquisition."
• Efficiencies to fund investment — CFO said operating efficiencies across the value chain (product mix maximization, production efficiencies) will fund most investment requirements; he hopes recent geopolitical developments could bring gross margin upside in FY 2027-2028, flowing back to the P&L for redeployment.
• Portfolio simplification ongoing — 6 brands and 350 SKUs rationalized to date, flagged as a continuing focus; SKUs will either see profitability enhanced or be exited, as mix will play an important role.
• D2C remains small — the Dabur shop is "very small" but beginning to grow, and "Signs by Dabur" is small but "growing handsomely"; management intends to accelerate the space to incubate D2C capabilities, and will look at parts of the higher end of the CESA portfolio to strengthen D2C.

FY 2026-2027 Guidance Reiterated; Growth Ambition Debate; Org Clarity

• FY 2026-2027 double-digit growth guidance reiterated — management delivered slightly ahead of this in H1 FY 2026-2027 and aims to maintain momentum for the remainder of FY 2026-2027.
• Growth ambition challenged — UBS analyst Amit Sarateva questioned why the framework is anchored to ~10% rather than 15%-20% growth (period unspecified); CEO rejected the status-quo characterization ("a big resounding no") but declined to commit to a formal 15%-20% ambition, saying the reimagined approach will focus on specific pockets capable of delivering 20%s, 30%s, 40%s and even 50% growth (period unspecified).
• Strategic exercise advanced ~1.5 years — underway in FY 2026-2027 versus its usual cycle; Bhalla positioned Dabur as "the poster child of for India, from India," noting presence in 8 out of 10 households in India.
• No new global/group CEO — per the Nov 3, 2026 announcement, Harjeet Bhalla has been inducted onto the board and continues to focus on the India and SAARC businesses plus board duties; the international business runs independently and will continue to do so; Mr. Narang (with the business for over 43 years) provides oversight, advice and guidance to all Dabur businesses.
• Consultant decision pending — no final decision on appointing a strategy consultant; expected "over the course of the next month" (i.e., by ~December 2026); McKinsey was the earlier strategy consultant as part of Vision 7.
• Efficiency-funded reinvestment mantra — "war on cost" with every rupee of spend delivering "bang for buck"; analyst Latika questioned whether the referenced 150 bps A&P increase (period unspecified) is sufficient given perceived underinvestment; the response emphasized efficiency-funded reinvestment rather than a larger A&P step-up.